Current Report Filing (8-k)
02 June 2022 - 6:06AM
Edgar (US Regulatory)
0001532346
false
0001532346
2022-06-01
2022-06-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 1, 2022
Atreca, Inc.
(Exact name of Registrant as Specified in Its
Charter)
Delaware |
001-38935 |
27-3723255 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
835 Industrial Rd., Suite 400 San Carlos, California |
|
94070 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(650) 595-2595
(Registrant’s Telephone Number, Including
Area Code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2.
below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Securities Exchange Act of 1934:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Class A Common Stock, $0.0001 par value per share |
|
BCEL |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 2.05 | Costs Associated with Exit or Disposal Activities |
On June 1, 2022,
Atreca, Inc. (the “Company”) implemented and announced a corporate reorganization of its operations.
In connection with the reorganization, the Company undertook a workforce reduction of more than 25%, including both current
employees and open positions, and expects to record severance and employee benefits charges of approximately
$0.7 million in the quarter ending June 30, 2022. As a result of the corporate reorganization, the Company believes its existing
cash, cash equivalents and investments will be sufficient to fund its operating and capital needs through 2023. The Company
will remain focused on the development of ATRC-101, ATRC-301, and its other preclinical oncology programs, and will continue its
efforts to generate new lead antibodies against tumor specific targets utilizing its proprietary discovery platform.
Forward-Looking Statements
Statements contained in this report regarding matters
that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform
Act of 1995. Words such as “expect,” “believe, “will,” “remain,” “continue” and
similar words are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements
regarding our strategy and future plans; expected severance and employee benefits charges in the quarter ending June 30, 2022; our
ability to fund our operating and capital needs through 2023; and our development of ATRC-101, ATRC-301, and our preclinical and clinical
plans. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties
related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials,
regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov, including
the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak
only as of the date of this report, and we undertake no obligation to update any forward-looking statement in this report, except as required
by law.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Atreca, Inc. |
|
|
|
|
Dated: June 1, 2022 |
By: |
/s/ John A. Orwin |
|
|
|
John A. Orwin |
|
|
President and Chief Executive Officer |
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024